2011
GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays
Li A, Liu Z, Lezon-Geyda K, Sarkar S, Lannin D, Schulz V, Krop I, Winer E, Harris L, Tuck D. GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays. Nucleic Acids Research 2011, 39: 4928-4941. PMID: 21398628, PMCID: PMC3130254, DOI: 10.1093/nar/gkr014.Peer-Reviewed Original Research
2008
Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis
Punglia RS, Burstein HJ, Winer EP, Weeks JC. Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis. Journal Of The National Cancer Institute 2008, 100: 642-648. PMID: 18445827, PMCID: PMC2864146, DOI: 10.1093/jnci/djn100.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Agents, HormonalAromatase InhibitorsBreast NeoplasmsChemotherapy, AdjuvantCytochrome P-450 CYP2D6Decision Support TechniquesDisease-Free SurvivalEstrogen Receptor ModulatorsFemaleGenotypeHumansMarkov ChainsMiddle AgedMutationNeoplasms, Hormone-DependentOdds RatioPostmenopauseReceptors, EstrogenSelective Estrogen Receptor ModulatorsTamoxifenConceptsDisease-free survivalWt/wt patientsAromatase inhibitorsBreast cancerCYP2D6 genotypeEndocrine therapyWT patientsNorth Central Cancer Treatment Group trialsEstrogen receptor-positive breast cancerBreast International Group (BIG) 1Optimal adjuvant endocrine therapyReceptor-positive breast cancerDisease-free survival outcomesAromatase inhibitor monotherapyAdjuvant endocrine therapyAdjuvant endocrine treatmentPostmenopausal breast cancerActive tamoxifen metabolitesBreast cancer patientsCytochrome P450 2D6Adjuvant tamoxifenEndocrine treatmentPostmenopausal womenHazard ratioInhibitor monotherapy
2007
Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer
Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC. Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer. Value In Health 2007, 10: 367-376. PMID: 17888101, DOI: 10.1111/j.1524-4733.2007.00190.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAndrostadienesAntineoplastic ProtocolsAromatase InhibitorsBreast NeoplasmsCost-Benefit AnalysisDrug Administration ScheduleFemaleForecastingHumansMarkov ChainsMiddle AgedNeoplasm Recurrence, LocalPostmenopauseQuality-Adjusted Life YearsSEER ProgramSelective Estrogen Receptor ModulatorsTamoxifenConceptsIntergroup Exemestane StudyDisease-free survivalDisease-related eventsTreatment strategiesEarly-stage breast cancer patientsEarly-stage breast cancerProlongs disease-free survivalCost-effective treatment strategyIncremental cost-effectiveness ratioYears of tamoxifenYears of therapyBreast cancer patientsSEER-Medicare dataBreast cancer statusLifetime medical care costsMedical care costsCost-effectiveness ratioTamoxifen therapyPostmenopausal womenRecurrence rateCancer careCancer patientsPatient transitionsAromatase inhibitorsBreast cancer
2006
The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer
Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer. Cancer 2006, 106: 2576-2582. PMID: 16703595, DOI: 10.1002/cncr.21919.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsBreast NeoplasmsChemotherapy, AdjuvantCross-Over StudiesDecision Support TechniquesDisease-Free SurvivalDrug Administration ScheduleFemaleHumansMarkov ChainsMiddle AgedModels, StatisticalModels, TheoreticalNeoplasm StagingOdds RatioPostmenopauseRandomized Controlled Trials as TopicReceptors, ProgesteroneTamoxifenTime FactorsTreatment OutcomeConceptsDisease-free survivalAromatase inhibitorsProgesterone receptorEstrogen receptorOptimal adjuvant endocrine therapyEarly-stage breast cancerAdjuvant endocrine therapyNode-positive groupProgesterone receptor statusRandomized clinical trialsSequential treatmentBreast cancer tumorsAI monotherapyAI therapyBiologic subsetsDFS ratesAdjuvant therapyEndocrine therapyPostmenopausal patientsPostmenopausal womenSequential therapyUpfront treatmentLymph nodesReceptor statusPR expression
2005
Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis
Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis. Journal Of Clinical Oncology 2005, 23: 5178-5187. PMID: 15998905, DOI: 10.1200/jco.2005.02.964.Peer-Reviewed Original ResearchConceptsDisease-free survivalDisease-free survival estimatesAromatase inhibitor monotherapyYears of tamoxifenAromatase inhibitorsSequential therapyBreast cancerInhibitor monotherapyPostmenopausal womenTreatment strategiesHormone receptor-positive breast cancerDisease-free survival ratesDistant disease-free survivalReceptor-positive breast cancerEarly-stage breast cancerSurvival estimatesAdjuvant endocrine therapyAromatase inhibitor therapyCross-over treatmentNode-positive patientsSequential adjuvant therapyPostmenopausal breast cancerRelative risk reductionRandomized clinical trialsSequential treatment strategy
2004
HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis
Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis. Journal Of Clinical Oncology 2004, 22: 854-863. PMID: 14990641, DOI: 10.1200/jco.2004.04.158.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBreast NeoplasmsCohort StudiesCost SavingsCost-Benefit AnalysisDecision Support TechniquesDose-Response Relationship, DrugDrug Administration ScheduleDrug CostsFemaleGenes, erbB-2Genetic TestingHealth Care CostsHumansMarkov ChainsNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingQuality of LifeSurvival RateTrastuzumabTreatment OutcomeConceptsIncremental cost-effectiveness ratioMetastatic breast cancer patientsBreast cancer patientsTrastuzumab therapyCancer patientsFavourable incremental cost-effectiveness ratioTest characteristicsMetastatic breast cancerCost-effectiveness ratioEffectiveness of treatmentPositive test resultsNegative test resultsPositive resultsCost-effectiveness analysisTreatment strategiesBreast cancerHypothetical cohortTreatment candidatesHercepTest resultsPatientsClinical practiceFISH confirmationProtein overexpressionLifetime costsHercepTest
1998
Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes
Tengs TO, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA. Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes. Medical Decision Making 1998, 18: 365-375. PMID: 10372578, DOI: 10.1177/0272989x9801800402.Peer-Reviewed Original ResearchAdultAgedBreast NeoplasmsDecision Support TechniquesFemaleGenes, BRCA1Genes, Tumor SuppressorGenetic Predisposition to DiseaseGenetic TestingHumansIncidenceMarkov ChainsMastectomyMiddle AgedOvarian NeoplasmsOvariectomyPredictive Value of TestsQuality-Adjusted Life YearsRisk AssessmentSurvival AnalysisUnited States